The viral vector and plasmid DNA manufacturing market offers growth opportunities in gene therapies, contract manufacturing, and emerging markets like Asia-Pacific. Key trends include rising demand ...
The globe viral vectors & plasmid DNA manufacturing market size is expected to be lead USD 29.82 billion by 2035, increasing ...
The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP ...
Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing demand. The purpose of the ...
Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...
So far, eight birds are confirmed to have died from the disease. Birds that have tested positive have been found in Burlingame (1), Redwood City (2 in the Redwood Shores area), San Carlos (1), and ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed and reproducibility, today announced the expansion of its ...
A global contract developer says it is among the first to offer a standardized approach to manufacturing adeno-associated viruses (AAVs) and lentiviruses (LVVs) for advanced therapies. AGC Biologics ...
LONDON, Sept. 14, 2023 /PRNewswire/ -- According to a comprehensive research report by Brandessence Market Research (BMRC), "Viral Vector Manufacturing Market Size, Share Outlook Growth By Top Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results